Lima Marco A
Arq Neuropsiquiatr. 2013 Sep;71(9B):699-702. doi: 10.1590/0004-282X20130154.
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the CNS caused by reactivation of JC virus (JCV) in a setting of cellular immunosuppression. Originally, PML was observed in patients with advanced HIV infection, lymphoproliferative disorders and transplant recipients. However, the widespread use of HIV antiretroviral drugs and the new selective immunomodulatory and immunosuppressive medications, such as Rituximab and Natalizumab, has recently modified the epidemiology, clinical presentation and prognosis of PML. Herein, we discuss the new concepts on PML, emphasizing the recent modification in the epidemiology; the impact of new immunomodulatory treatments in the disease, PML-IRIS (Immune reconstitution inflammatory syndrome), new treatment strategies and other JCV related CNS diseases.
进行性多灶性白质脑病(PML)是一种中枢神经系统脱髓鞘疾病,由JC病毒(JCV)在细胞免疫抑制的情况下重新激活所致。最初,PML在晚期HIV感染患者、淋巴增殖性疾病患者和移植受者中被观察到。然而,HIV抗逆转录病毒药物以及新的选择性免疫调节和免疫抑制药物(如利妥昔单抗和那他珠单抗)的广泛使用,最近改变了PML的流行病学、临床表现和预后。在此,我们讨论PML的新概念,重点强调流行病学的最新变化;新的免疫调节治疗对该疾病的影响、PML-IRIS(免疫重建炎症综合征)、新的治疗策略以及其他与JCV相关的中枢神经系统疾病。